How many 8-K filings has Kalvista Pharmaceuticals, Inc. filed?

Kalvista Pharmaceuticals, Inc. (KALV) has 22 8-K (Current Event Report) filings on record, spanning Feb 2024 to Mar 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Kalvista Pharmaceuticals, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Kalvista Pharmaceuticals, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Kalvista Pharmaceuticals, Inc. (KALV) — 8-K Filings

All 8-K filings from Kalvista Pharmaceuticals, Inc.. Browse 22 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (22)

KalVista Files 8-K on Financial Results & Operations — Mar 25, 2026
KalVista Pharmaceuticals, Inc. filed an 8-K on March 25, 2026, primarily disclosing its results of operations and financial condition under Item 2.02. This fili
KalVista Pharmaceuticals Files 8-K on Officer/Director Changes — Oct 6, 2025 Risk: low
KalVista Pharmaceuticals, Inc. filed an 8-K on October 6, 2025, reporting on the departure of directors or certain officers, election of directors, appointment
KalVista Pharmaceuticals Files 8-K: Director Changes & Officer Compensation Updates — Oct 2, 2025 Risk: low
On October 1, 2025, KalVista Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the elec
KalVista Pharmaceuticals Files 8-K on Agreements and Equity Sales — Sep 29, 2025 Risk: medium
On September 24, 2025, KalVista Pharmaceuticals, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company als
KalVista Pharmaceuticals, Inc. Files 8-K — Aug 21, 2025 Risk: low
On August 21, 2025, KalVista Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's former name from Carbylan Therapeutics, I
KalVista Pharmaceuticals Files 8-K on Financials — Jul 10, 2025 Risk: low
On July 10, 2025, KalVista Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
KalVista Pharmaceuticals Files 8-K Report — Jul 7, 2025 Risk: low
On July 7, 2025, KalVista Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events an
KalVista Pharmaceuticals Announces Board and Compensation Changes — May 12, 2025 Risk: medium
On May 12, 2025, KalVista Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates
KalVista Pharmaceuticals Files 8-K with Material Agreement Details — Apr 8, 2025 Risk: medium
On April 8, 2025, KalVista Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosur
KalVista Pharmaceuticals Changes Fiscal Year End — Mar 17, 2025 Risk: low
KalVista Pharmaceuticals, Inc. filed an 8-K on March 17, 2025, reporting a change in its fiscal year end from April 30 to March 13, effective March 13, 2025. Th
KalVista Pharmaceuticals Files 8-K with Board and Compensation Updates — Dec 16, 2024 Risk: medium
On December 16, 2024, KalVista Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. Th
KalVista Pharmaceuticals Files 8-K — Dec 5, 2024 Risk: low
KalVista Pharmaceuticals, Inc. filed an 8-K on December 5, 2024, to report on its results of operations and financial condition, and to file financial statement
KalVista Pharma Appoints New CMO, Director — Nov 26, 2024 Risk: medium
KalVista Pharmaceuticals, Inc. announced on November 23, 2024, the appointment of Dr. Andrew Sinclair as Chief Medical Officer and the election of Ms. Sarah Kel
KalVista Pharmaceuticals Files 8-K — Nov 4, 2024 Risk: medium
On November 4, 2024, KalVista Pharmaceuticals, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial
KalVista Pharmaceuticals Files 8-K on Shareholder Votes — Oct 4, 2024 Risk: low
KalVista Pharmaceuticals, Inc. filed an 8-K on October 3, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain sp
KalVista Pharmaceuticals Announces Executive and Board Changes — Sep 10, 2024 Risk: medium
KalVista Pharmaceuticals, Inc. announced on September 6, 2024, a series of executive and board changes. Dr. Andrew Sinclair has been appointed as the new Chief
KalVista Pharma Secures $75M Loan Facility — Jul 23, 2024 Risk: medium
On July 22, 2024, KalVista Pharmaceuticals, Inc. entered into a material definitive agreement, specifically a loan and security agreement with Hercules Capital,
KalVista Pharma Appoints New CMO, Elects Director — Apr 22, 2024 Risk: medium
KalVista Pharmaceuticals, Inc. announced on April 18, 2024, the appointment of Dr. Andrew Sinclair as Chief Medical Officer and the election of Dr. Sarah Schles
KalVista Pharma Appoints New CMO, Director — Mar 7, 2024 Risk: low
KalVista Pharmaceuticals, Inc. announced on March 6, 2024, the appointment of Dr. Andrew Hinton as Chief Medical Officer and the election of Dr. Michael Stein a
KalVista Pharmaceuticals Reports Material Agreement and Financials — Feb 16, 2024 Risk: medium
KalVista Pharmaceuticals, Inc. filed an 8-K on February 16, 2024, reporting an event that occurred on February 14, 2024. The filing indicates an entry into a ma
KalVista Pharmaceuticals Terminates Material Agreement — Feb 14, 2024 Risk: medium
KalVista Pharmaceuticals, Inc. filed an 8-K on February 14, 2024, reporting the termination of a material definitive agreement. This event, which was the earlie
KalVista Pharmaceuticals Files 8-K on Feb 13, 2024 — Feb 13, 2024 Risk: medium
KalVista Pharmaceuticals, Inc. filed an 8-K on February 13, 2024, reporting under Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX